Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced the completion of a multifold oversubscribed $157 million Series C financing round. The round was led by Sofinnova Partners with substantial participation from a large long-only global asset management company, and participation from additional new investors including a large global sovereign wealth fund, and Avoro Capital Advisors, alongside existing investors RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital. In connection with this financing, Joe Anderson, PhD, Partner at Sofinnova Partners, will join the Hemab Board.